2025 H1 -tulosraportti
110 päivää sitten38 min
Tarjoustasot
Oslo Børs
Määrä
Osto
26 854
Myynti
Määrä
1 801
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 089 | - | - | ||
| 10 357 | - | - | ||
| 2 735 | - | - | ||
| 3 819 | - | - | ||
| 20 783 | - | - |
Ylin
4,375VWAP
Alin
4,19VaihtoMäärä
5,6 1 296 543
VWAP
Ylin
4,375Alin
4,19VaihtoMäärä
5,6 1 296 543
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 26.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 H1 -tulosraportti | 29.8. | |
| 2025 Q2 -tulosraportti | 29.8. | |
| 2024 H2 -tulosraportti | 26.2. | |
| 2024 Q4 -tulosraportti | 26.2. | |
| 2024 H1 -tulosraportti | 30.8.2024 |
Datan lähde: FactSet, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·6 t sittenDon't blindly trust AI but can one disagree?: Are we seeing a cup and handle in Thor Medical here? 1️⃣ The Cup – YES, quite clear • Left side: The price is flat/low around 2,4–2,6 in July • Bottom: Round and stable (no V-shape) • Right side: Strong rise towards 4,8–5,0 in September 👉 This is a classic rounded cup: • Duration: several months ✅ • Shape: U-shape, not V ✅ • Rise back to previous peak area ✅ Cup depth approx.: • Top ~4,8 • Bottom ~2,5 • Depth ~2,3 kr ⸻ 2️⃣ The Handle – YES, and it is healthy After the September peak: • Sharp drop towards 3,4–3,6 • Then sideways / slightly rising consolidation • Duration: several weeks • Volatility decreases 👉 This is very typical handle: • Approx. 30–40 % of the cup's height (a bit deep, but within range for volatile stocks) • No new lower bottom • “Shakes off” short-term holders ⸻ 3️⃣ The Breakout Phase – NOW ONGOING • Current price: 4,34 • Recent breakout from consolidation around 4,0 • Testing the resistance zone 4,5–4,8 again 👉 This is often the phase where: • Either a confirmed breakout occurs • Or a final pullback before a new attempt ⸻ 🎯 Classic price target (technical) Cup depth ≈ 2,3 kr If clear breakout above: • Resistance: 4,8–5,0 ➡️ Technical price target: 7,0–7,3 kr (over time, not straight up) ⸻ ⚠️ Important levels to follow Support: • 4,0 (handle top) • 3,6 (critical – below here the pattern weakens) Resistance: • 4,8–5,0 (key level) • Above 5 → very bullish technically ⸻ 🧠 Conclusion (honest and precise) 📌 Yes – this is one of the better cup and handle tendencies I have seen in Thor. ✔️ Correct shape ✔️ Correct duration ✔️ Healthy consolidation ✔️ Breakout attempt underway The only thing remaining for full confirmation: 👉 Clear breakout above 4,8–5,0 with volume
·9 t sittenIs the cup and handle position soon in the bag?🏎️🏁
·6 t sittenAnd when is the date for this???
·10 t sittenDo you have more than 50% of your holdings in Thor Medical?75 ääntä 13 tuntia jäljelläLiity Sharevilleen osallistuaksesi kyselyyn·9 t sittenNo wonder the comment section here is buzzing at the slightest movements =)
·14 t sittenI'm taking a chance with some AI again, as I can't see anything wrong here : Thor Medical has had a very active period now at the end of 2025, characterized by several major supply agreements and positive development on the stock exchange. Here are the most important news from the company: 1. Major supply agreements in the USA and Norway The company has recently secured several strategic framework agreements for the supply of Thorium-228 (Th-228), which is crucial for next-generation cancer treatment: RadioMedix (December 2025): Thor Medical entered into a five-year agreement with the American biotechnology company RadioMedix. Deliveries start in 2026 and will escalate in line with production at Thor Medical's AlphaOne facility. NucliThera (November 2025): A five-year framework agreement was signed with Norwegian NucliThera for the use of isotopes in their development programs for blood cancer. Telix Pharmaceuticals (November 2025): A strategic master agreement was signed with Australian Telix, one of the global leaders in radiopharmaceuticals. 2. Production and capacity Thor Medical has significantly increased its production rate in 2025. The company reported this autumn a streamlined process where, in the first quarter alone, they processed more thorium than anticipated for the entire year. They have recently applied for expanded emission permits to be able to handle larger volumes at their facility at Herøya/Oslo. 3. Share and finance Share price development: The share (TRMED) has shown a strong trend in December. As of December 16, 2025, the price is around 4.20 NOK, and technical analyses indicate a rising trend channel with increasing optimism among investors. Capital changes: The company has recently registered new share capital after previous issues, which has strengthened the financial position for further commercialization. 4. Strengthening of management In November, the management team was strengthened to support the company's ambition to become a leading global supplier of alpha-emitters. This includes a focus on scaling from pilot operation to full commercial production. In summary: Thor Medical is in the process of transitioning from being a development company to becoming a commercial supplier with a solid order book towards 2026.- ·15 t sittenChristmas rocket🚀?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 H1 -tulosraportti
110 päivää sitten38 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·6 t sittenDon't blindly trust AI but can one disagree?: Are we seeing a cup and handle in Thor Medical here? 1️⃣ The Cup – YES, quite clear • Left side: The price is flat/low around 2,4–2,6 in July • Bottom: Round and stable (no V-shape) • Right side: Strong rise towards 4,8–5,0 in September 👉 This is a classic rounded cup: • Duration: several months ✅ • Shape: U-shape, not V ✅ • Rise back to previous peak area ✅ Cup depth approx.: • Top ~4,8 • Bottom ~2,5 • Depth ~2,3 kr ⸻ 2️⃣ The Handle – YES, and it is healthy After the September peak: • Sharp drop towards 3,4–3,6 • Then sideways / slightly rising consolidation • Duration: several weeks • Volatility decreases 👉 This is very typical handle: • Approx. 30–40 % of the cup's height (a bit deep, but within range for volatile stocks) • No new lower bottom • “Shakes off” short-term holders ⸻ 3️⃣ The Breakout Phase – NOW ONGOING • Current price: 4,34 • Recent breakout from consolidation around 4,0 • Testing the resistance zone 4,5–4,8 again 👉 This is often the phase where: • Either a confirmed breakout occurs • Or a final pullback before a new attempt ⸻ 🎯 Classic price target (technical) Cup depth ≈ 2,3 kr If clear breakout above: • Resistance: 4,8–5,0 ➡️ Technical price target: 7,0–7,3 kr (over time, not straight up) ⸻ ⚠️ Important levels to follow Support: • 4,0 (handle top) • 3,6 (critical – below here the pattern weakens) Resistance: • 4,8–5,0 (key level) • Above 5 → very bullish technically ⸻ 🧠 Conclusion (honest and precise) 📌 Yes – this is one of the better cup and handle tendencies I have seen in Thor. ✔️ Correct shape ✔️ Correct duration ✔️ Healthy consolidation ✔️ Breakout attempt underway The only thing remaining for full confirmation: 👉 Clear breakout above 4,8–5,0 with volume
- ·9 t sittenIs the cup and handle position soon in the bag?🏎️🏁·6 t sittenAnd when is the date for this???
- ·10 t sittenDo you have more than 50% of your holdings in Thor Medical?75 ääntä 13 tuntia jäljelläLiity Sharevilleen osallistuaksesi kyselyyn·9 t sittenNo wonder the comment section here is buzzing at the slightest movements =)
- ·14 t sittenI'm taking a chance with some AI again, as I can't see anything wrong here : Thor Medical has had a very active period now at the end of 2025, characterized by several major supply agreements and positive development on the stock exchange. Here are the most important news from the company: 1. Major supply agreements in the USA and Norway The company has recently secured several strategic framework agreements for the supply of Thorium-228 (Th-228), which is crucial for next-generation cancer treatment: RadioMedix (December 2025): Thor Medical entered into a five-year agreement with the American biotechnology company RadioMedix. Deliveries start in 2026 and will escalate in line with production at Thor Medical's AlphaOne facility. NucliThera (November 2025): A five-year framework agreement was signed with Norwegian NucliThera for the use of isotopes in their development programs for blood cancer. Telix Pharmaceuticals (November 2025): A strategic master agreement was signed with Australian Telix, one of the global leaders in radiopharmaceuticals. 2. Production and capacity Thor Medical has significantly increased its production rate in 2025. The company reported this autumn a streamlined process where, in the first quarter alone, they processed more thorium than anticipated for the entire year. They have recently applied for expanded emission permits to be able to handle larger volumes at their facility at Herøya/Oslo. 3. Share and finance Share price development: The share (TRMED) has shown a strong trend in December. As of December 16, 2025, the price is around 4.20 NOK, and technical analyses indicate a rising trend channel with increasing optimism among investors. Capital changes: The company has recently registered new share capital after previous issues, which has strengthened the financial position for further commercialization. 4. Strengthening of management In November, the management team was strengthened to support the company's ambition to become a leading global supplier of alpha-emitters. This includes a focus on scaling from pilot operation to full commercial production. In summary: Thor Medical is in the process of transitioning from being a development company to becoming a commercial supplier with a solid order book towards 2026.
- ·15 t sittenChristmas rocket🚀?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
26 854
Myynti
Määrä
1 801
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 089 | - | - | ||
| 10 357 | - | - | ||
| 2 735 | - | - | ||
| 3 819 | - | - | ||
| 20 783 | - | - |
Ylin
4,375VWAP
Alin
4,19VaihtoMäärä
5,6 1 296 543
VWAP
Ylin
4,375Alin
4,19VaihtoMäärä
5,6 1 296 543
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 26.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 H1 -tulosraportti | 29.8. | |
| 2025 Q2 -tulosraportti | 29.8. | |
| 2024 H2 -tulosraportti | 26.2. | |
| 2024 Q4 -tulosraportti | 26.2. | |
| 2024 H1 -tulosraportti | 30.8.2024 |
Datan lähde: FactSet, Quartr
2025 H1 -tulosraportti
110 päivää sitten38 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 26.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 H1 -tulosraportti | 29.8. | |
| 2025 Q2 -tulosraportti | 29.8. | |
| 2024 H2 -tulosraportti | 26.2. | |
| 2024 Q4 -tulosraportti | 26.2. | |
| 2024 H1 -tulosraportti | 30.8.2024 |
Datan lähde: FactSet, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·6 t sittenDon't blindly trust AI but can one disagree?: Are we seeing a cup and handle in Thor Medical here? 1️⃣ The Cup – YES, quite clear • Left side: The price is flat/low around 2,4–2,6 in July • Bottom: Round and stable (no V-shape) • Right side: Strong rise towards 4,8–5,0 in September 👉 This is a classic rounded cup: • Duration: several months ✅ • Shape: U-shape, not V ✅ • Rise back to previous peak area ✅ Cup depth approx.: • Top ~4,8 • Bottom ~2,5 • Depth ~2,3 kr ⸻ 2️⃣ The Handle – YES, and it is healthy After the September peak: • Sharp drop towards 3,4–3,6 • Then sideways / slightly rising consolidation • Duration: several weeks • Volatility decreases 👉 This is very typical handle: • Approx. 30–40 % of the cup's height (a bit deep, but within range for volatile stocks) • No new lower bottom • “Shakes off” short-term holders ⸻ 3️⃣ The Breakout Phase – NOW ONGOING • Current price: 4,34 • Recent breakout from consolidation around 4,0 • Testing the resistance zone 4,5–4,8 again 👉 This is often the phase where: • Either a confirmed breakout occurs • Or a final pullback before a new attempt ⸻ 🎯 Classic price target (technical) Cup depth ≈ 2,3 kr If clear breakout above: • Resistance: 4,8–5,0 ➡️ Technical price target: 7,0–7,3 kr (over time, not straight up) ⸻ ⚠️ Important levels to follow Support: • 4,0 (handle top) • 3,6 (critical – below here the pattern weakens) Resistance: • 4,8–5,0 (key level) • Above 5 → very bullish technically ⸻ 🧠 Conclusion (honest and precise) 📌 Yes – this is one of the better cup and handle tendencies I have seen in Thor. ✔️ Correct shape ✔️ Correct duration ✔️ Healthy consolidation ✔️ Breakout attempt underway The only thing remaining for full confirmation: 👉 Clear breakout above 4,8–5,0 with volume
- ·9 t sittenIs the cup and handle position soon in the bag?🏎️🏁·6 t sittenAnd when is the date for this???
- ·10 t sittenDo you have more than 50% of your holdings in Thor Medical?75 ääntä 13 tuntia jäljelläLiity Sharevilleen osallistuaksesi kyselyyn·9 t sittenNo wonder the comment section here is buzzing at the slightest movements =)
- ·14 t sittenI'm taking a chance with some AI again, as I can't see anything wrong here : Thor Medical has had a very active period now at the end of 2025, characterized by several major supply agreements and positive development on the stock exchange. Here are the most important news from the company: 1. Major supply agreements in the USA and Norway The company has recently secured several strategic framework agreements for the supply of Thorium-228 (Th-228), which is crucial for next-generation cancer treatment: RadioMedix (December 2025): Thor Medical entered into a five-year agreement with the American biotechnology company RadioMedix. Deliveries start in 2026 and will escalate in line with production at Thor Medical's AlphaOne facility. NucliThera (November 2025): A five-year framework agreement was signed with Norwegian NucliThera for the use of isotopes in their development programs for blood cancer. Telix Pharmaceuticals (November 2025): A strategic master agreement was signed with Australian Telix, one of the global leaders in radiopharmaceuticals. 2. Production and capacity Thor Medical has significantly increased its production rate in 2025. The company reported this autumn a streamlined process where, in the first quarter alone, they processed more thorium than anticipated for the entire year. They have recently applied for expanded emission permits to be able to handle larger volumes at their facility at Herøya/Oslo. 3. Share and finance Share price development: The share (TRMED) has shown a strong trend in December. As of December 16, 2025, the price is around 4.20 NOK, and technical analyses indicate a rising trend channel with increasing optimism among investors. Capital changes: The company has recently registered new share capital after previous issues, which has strengthened the financial position for further commercialization. 4. Strengthening of management In November, the management team was strengthened to support the company's ambition to become a leading global supplier of alpha-emitters. This includes a focus on scaling from pilot operation to full commercial production. In summary: Thor Medical is in the process of transitioning from being a development company to becoming a commercial supplier with a solid order book towards 2026.
- ·15 t sittenChristmas rocket🚀?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
26 854
Myynti
Määrä
1 801
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 089 | - | - | ||
| 10 357 | - | - | ||
| 2 735 | - | - | ||
| 3 819 | - | - | ||
| 20 783 | - | - |
Ylin
4,375VWAP
Alin
4,19VaihtoMäärä
5,6 1 296 543
VWAP
Ylin
4,375Alin
4,19VaihtoMäärä
5,6 1 296 543
Välittäjätilasto
Dataa ei löytynyt